Last reviewed · How we verify
CINRYZE 1000 U
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces or augments deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces or augments deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks. Used for Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis.
At a glance
| Generic name | CINRYZE 1000 U |
|---|---|
| Sponsor | Shire |
| Drug class | C1 esterase inhibitor (C1-INH) replacement therapy |
| Target | C1 esterase inhibitor (C1-INH); contact system cascade (Factor XII, kallikrein pathway) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rare Genetic Disorders |
| Phase | Phase 3 |
Mechanism of action
Hereditary angioedema (HAE) results from deficiency or dysfunction of C1 esterase inhibitor, a regulatory protein in the contact system cascade. Without adequate C1-INH, uncontrolled activation of Factor XII and kallikrein leads to excessive bradykinin production, causing severe angioedema. CINRYZE provides exogenous C1-INH to restore normal regulation of this cascade and prevent or reduce the frequency and severity of angioedema attacks.
Approved indications
- Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis
Common side effects
- Headache
- Nausea
- Vomiting
- Infusion site reactions
- Thrombosis (rare)
Key clinical trials
- CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 (PHASE2)
- Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CINRYZE 1000 U CI brief — competitive landscape report
- CINRYZE 1000 U updates RSS · CI watch RSS
- Shire portfolio CI